M A O'Rorke1, L J Murray2, J S Brand3, N Bhoo-Pathy4. 1. Centre for Public Health, Queen's University Belfast, Royal Victoria Hospital Site, Grosvenor Road, Belfast BT12 6BJ, United Kingdom. Electronic address: m.ororke@qub.ac.uk. 2. Centre for Public Health, Queen's University Belfast, Royal Victoria Hospital Site, Grosvenor Road, Belfast BT12 6BJ, United Kingdom. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, 17177 Stockholm, Sweden. 4. Julius Centre University of Malaya (JCUM), Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia.
Abstract
BACKGROUND: The value of adjuvant radiotherapy in triple negative breast cancer (TNBC) remains unclear. A systematic review and meta-analysis was conducted in TNBC patients to assess survival and recurrence outcomes associated with radiotherapy following either breast conserving therapy (BCT) or post-mastectomy radiotherapy (PMRT). METHODS: Four electronic databases were searched from January 2000 to November 2015 (PubMed, MEDLINE, EMBASE and Web of Science). Studies investigating overall survival and/or recurrence in TNBC patients according to radiotherapy administration were included. A random effects meta-analysis was conducted using mastectomy only patients as the reference. RESULTS: Twelve studies were included. The pooled hazard ratio (HR) for locoregional recurrence comparing BCT and PMRT to mastectomy only was 0.61 (95% confidence interval [CI] 0.41-0.90) and 0.62 (95% CI 0.44-0.86), respectively. Adjuvant radiotherapy was not significantly associated with distant recurrence. The pooled HR for overall survival comparing BCT and PMRT to mastectomy only was 0.57 (95% CI 0.36-0.88) and HR 1.12 (95% CI 0.75, 1.69). Comparing PMRT to mastectomy only, tests for interaction were not significant for stage (p=0.98) or age at diagnosis (p=0.85). However, overall survival was improved in patients with late-stage disease (T3-4, N2-3) pooled HR 0.53 (95% CI 0.32-0.86), and women <40years, pooled HR 0.30 (95% CI 0.11-0.82). CONCLUSIONS: Adjuvant radiotherapy was associated with a significantly lower risk of locoregional recurrence in TNBC patients, irrespective of the type of surgery. While radiotherapy was not consistently associated with an overall survival gain, benefits may be obtained in women with late-stage disease and younger patients.
BACKGROUND: The value of adjuvant radiotherapy in triple negative breast cancer (TNBC) remains unclear. A systematic review and meta-analysis was conducted in TNBC patients to assess survival and recurrence outcomes associated with radiotherapy following either breast conserving therapy (BCT) or post-mastectomy radiotherapy (PMRT). METHODS: Four electronic databases were searched from January 2000 to November 2015 (PubMed, MEDLINE, EMBASE and Web of Science). Studies investigating overall survival and/or recurrence in TNBC patients according to radiotherapy administration were included. A random effects meta-analysis was conducted using mastectomy only patients as the reference. RESULTS: Twelve studies were included. The pooled hazard ratio (HR) for locoregional recurrence comparing BCT and PMRT to mastectomy only was 0.61 (95% confidence interval [CI] 0.41-0.90) and 0.62 (95% CI 0.44-0.86), respectively. Adjuvant radiotherapy was not significantly associated with distant recurrence. The pooled HR for overall survival comparing BCT and PMRT to mastectomy only was 0.57 (95% CI 0.36-0.88) and HR 1.12 (95% CI 0.75, 1.69). Comparing PMRT to mastectomy only, tests for interaction were not significant for stage (p=0.98) or age at diagnosis (p=0.85). However, overall survival was improved in patients with late-stage disease (T3-4, N2-3) pooled HR 0.53 (95% CI 0.32-0.86), and women <40years, pooled HR 0.30 (95% CI 0.11-0.82). CONCLUSIONS: Adjuvant radiotherapy was associated with a significantly lower risk of locoregional recurrence in TNBC patients, irrespective of the type of surgery. While radiotherapy was not consistently associated with an overall survival gain, benefits may be obtained in women with late-stage disease and younger patients.
Authors: Tong Liu; Hao Zhang; Li Sun; Danyu Zhao; Peng Liu; Meisi Yan; Neeha Zaidi; Sudeh Izadmehr; Animesh Gupta; Wahid Abu-Amer; Minna Luo; Jie Yang; Xunyan Ou; Yining Wang; Xuefeng Bai; Yan Wang; Maria I New; Mone Zaidi; Tony Yuen; Caigang Liu Journal: Proc Natl Acad Sci U S A Date: 2017-07-03 Impact factor: 11.205
Authors: Janet L Martin; Sohel M Julovi; Mike Z Lin; Hasanthi C de Silva; Frances M Boyle; Robert C Baxter Journal: Breast Cancer Res Date: 2017-08-04 Impact factor: 6.466
Authors: S Sinnadurai; A Kwong; M Hartman; E Y Tan; N T Bhoo-Pathy; M Dahlui; M H See; C H Yip; N A Taib; N Bhoo-Pathy Journal: BJS Open Date: 2018-10-18
Authors: Hesham Elghazaly; Hope S Rugo; Hamdy A Azim; Sandra M Swain; Banu Arun; Matti Aapro; Edith A Perez; Benjamin O Anderson; Frederique Penault-Llorca; Pierfranco Conte; Nagi S El Saghir; Cheng-Har Yip; Marwan Ghosn; Philip Poortmans; Mohamed A Shehata; Armando E Giuliano; Jessica W T Leung; Valentina Guarneri; Joseph Gligorov; Bahadir M Gulluoglu; Hany Abdel Aziz; Mona Frolova; Mohamed Sabry; Charles M Balch; Roberto Orecchia; Heba M El-Zawahry; Sana Al-Sukhun; Khaled Abdel Karim; Alaa Kandil; Ruslan M Paltuev; Meteb Foheidi; Mohamed El-Shinawi; Manal ElMahdy; Omalkhair Abulkhair; Wentao Yang; Adel T Aref; Joaira Bakkach; Nermean Bahie Eldin; Hagar Elghazawy Journal: Cancers (Basel) Date: 2021-05-08 Impact factor: 6.639
Authors: Demet Candas-Green; Bowen Xie; Jie Huang; Ming Fan; Aijun Wang; Cheikh Menaa; Yanhong Zhang; Lu Zhang; Di Jing; Soheila Azghadi; Weibing Zhou; Lin Liu; Nian Jiang; Tao Li; Tianyi Gao; Colleen Sweeney; Rulong Shen; Tzu-Yin Lin; Chong-Xian Pan; Omer M Ozpiskin; Gayle Woloschak; David J Grdina; Andrew T Vaughan; Ji Ming Wang; Shuli Xia; Arta M Monjazeb; William J Murphy; Lun-Quan Sun; Hong-Wu Chen; Kit S Lam; Ralph R Weichselbaum; Jian Jian Li Journal: Nat Commun Date: 2020-09-14 Impact factor: 14.919